Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation With CELLECTRA-5PSP for the Treatment of HPV-16 and/or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) of the Cervix

Trial Profile

A Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation With CELLECTRA-5PSP for the Treatment of HPV-16 and/or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) of the Cervix

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VGX 3100 (Primary)
  • Indications Cervical intraepithelial neoplasia; Human papillomavirus infections
  • Focus Registrational; Therapeutic Use
  • Acronyms REVEAL 1
  • Sponsors Inovio Pharmaceuticals
  • Most Recent Events

    • 26 Jun 2019 According to an Inovio Pharmaceuticals media release,status changed from recruiting to active, no longer recruiting.
    • 07 Mar 2019 Planned End Date changed from 1 Aug 2020 to 1 Apr 2021.
    • 07 Mar 2019 Planned primary completion date changed from 1 Aug 2019 to 1 Apr 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top